科研之友
微信
新浪微博
Facebook
分享链接
摘要
2011 saw improvements in our understanding of B-cell malignancies: insights into the genomic basis of chronic lymphocytic leukemia were achieved; reduced treatment intensity caused fewer toxic effects in early-stage Hodgkin lymphoma; first-line rituximab maintenance therapy improved outcome in follicular lymphoma; and selected patients with diffuse large-cell lymphoma benefited from the addition of bortezomib. Cramer, P. %26 Hallek, M. Nat. Rev. Clin. Oncol. 9, 72-74 (2012); published online 10 January 2012; doi:10.1038/nrclinonc.2011.212
- 出版日期2012-2
